Jourdan J L, Akhter J, Bowrey P, Pourgholami M, Morris D L
University of New South Wales, Department of Surgery, St George Hospital, Kogarah, Sydney, Australia.
Anticancer Res. 2000 Jul-Aug;20(4):2739-44.
1,25-(OH)2 D3 has an in vitro growth regulator effect on different cancers. Unfortunately, dose-limiting toxicity (hypercalcemia) limits its use in anticancer therapy. For primary liver tumors, loco-regional delivery of 1,25-(OH)2 D3 in lipiodol might avoid high systemic concentrations and development of hypercalcemia.
1,25-(OH)2 D3 alone or mixed in lipiodol, was delivered at different concentrations into the hepatic artery of rats bearing a primary liver tumor. Calcium levels, tumor volume and proliferation index were assessed after treatment.
Serum calcium values were significantly lower when the drug was mixed into lipiodol. Treatment with 10 micrograms of 1,25-(OH)2 D3 in ethanol resulted in a decrease in proliferation index within the tumor.
The delivery of 1,25-(OH)2 D3 mixed in lipiodol reduces the subsequent elevation of serum calcium. Locoregional treatment with 1,25-(OH)2 D3 was shown for the first time to be effective on primary liver tumor growth in vivo.
1,25 -（OH）₂D₃对不同癌症具有体外生长调节作用。遗憾的是，剂量限制性毒性（高钙血症）限制了其在抗癌治疗中的应用。对于原发性肝癌，将1,25 -（OH）₂D₃通过碘化油进行局部区域给药可能避免高全身浓度以及高钙血症的发生。
单独的1,25 -（OH）₂D₃或与碘化油混合后，以不同浓度注入患有原发性肝癌的大鼠肝动脉。治疗后评估钙水平、肿瘤体积和增殖指数。
当药物与碘化油混合时，血清钙值显著降低。用10微克乙醇溶液中的1,25 -（OH）₂D₃治疗可使肿瘤内增殖指数降低。
与碘化油混合的1,25 -（OH）₂D₃给药可降低随后血清钙的升高。首次表明1,25 -（OH）₂D₃局部区域治疗对原发性肝癌的体内生长有效。
